The development of novel therapies for rheumatoid arthritis

Ling Dong Quan, Geoffrey Milton Thiele, Jun Tian, Dong Wang

Research output: Contribution to journalReview article

92 Citations (Scopus)

Abstract

Background: Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease that affects approximately 0.5 - 1% of adults worldwide and commonly results in joint destruction and significant impairment in the quality of life. RA is considered an autoimmune disease with unknown etiology. Many pathogenic pathways of RA have been revealed recently, which has led to development of various novel therapies. Objective: The current treatments for RA fall into four categories: non-steroidal anti-inflammatory drugs, glucocorticoids, non-biological, disease-modifying anti-rheumatic drugs (DMARDs) and biological DMARDs. In this review, we discuss some of the most recent development in antirheumatic therapies. Methods: Using SciFinder Scholar and PubMed as our main search tools, we evaluated various newly developed therapies for RA. In each drug category, emphases are placed on the mode of action, limitations and new drug candidates from the patent search. Those therapies that are well-established are reviewed only briefly. Conclusion: During the past 20 years, most of the development of new therapies is in DMARDs, especially biological DMARDs. With the discovery of new pathways and the application of drug delivery strategies, more growth is anticipated in this research field.

Original languageEnglish (US)
Pages (from-to)723-738
Number of pages16
JournalExpert Opinion on Therapeutic Patents
Volume18
Issue number7
DOIs
StatePublished - Jul 1 2008

Fingerprint

Antirheumatic Agents
Rheumatoid Arthritis
drug
Disease
Pharmaceutical Preparations
Therapeutics
PubMed
Glucocorticoids
Autoimmune Diseases
Anti-Inflammatory Agents
Joints
Quality of Life
etiology
field research
patent
Growth
quality of life
Research
candidacy

Keywords

  • DMARDs
  • Drug delivery
  • Glucocorticoids
  • NSAIDs
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

The development of novel therapies for rheumatoid arthritis. / Quan, Ling Dong; Thiele, Geoffrey Milton; Tian, Jun; Wang, Dong.

In: Expert Opinion on Therapeutic Patents, Vol. 18, No. 7, 01.07.2008, p. 723-738.

Research output: Contribution to journalReview article

@article{cd8b434ccb1b433b9d4e7d7a5d85461d,
title = "The development of novel therapies for rheumatoid arthritis",
abstract = "Background: Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease that affects approximately 0.5 - 1{\%} of adults worldwide and commonly results in joint destruction and significant impairment in the quality of life. RA is considered an autoimmune disease with unknown etiology. Many pathogenic pathways of RA have been revealed recently, which has led to development of various novel therapies. Objective: The current treatments for RA fall into four categories: non-steroidal anti-inflammatory drugs, glucocorticoids, non-biological, disease-modifying anti-rheumatic drugs (DMARDs) and biological DMARDs. In this review, we discuss some of the most recent development in antirheumatic therapies. Methods: Using SciFinder Scholar and PubMed as our main search tools, we evaluated various newly developed therapies for RA. In each drug category, emphases are placed on the mode of action, limitations and new drug candidates from the patent search. Those therapies that are well-established are reviewed only briefly. Conclusion: During the past 20 years, most of the development of new therapies is in DMARDs, especially biological DMARDs. With the discovery of new pathways and the application of drug delivery strategies, more growth is anticipated in this research field.",
keywords = "DMARDs, Drug delivery, Glucocorticoids, NSAIDs, Rheumatoid arthritis",
author = "Quan, {Ling Dong} and Thiele, {Geoffrey Milton} and Jun Tian and Dong Wang",
year = "2008",
month = "7",
day = "1",
doi = "10.1517/13543776.18.7.723",
language = "English (US)",
volume = "18",
pages = "723--738",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - The development of novel therapies for rheumatoid arthritis

AU - Quan, Ling Dong

AU - Thiele, Geoffrey Milton

AU - Tian, Jun

AU - Wang, Dong

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Background: Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease that affects approximately 0.5 - 1% of adults worldwide and commonly results in joint destruction and significant impairment in the quality of life. RA is considered an autoimmune disease with unknown etiology. Many pathogenic pathways of RA have been revealed recently, which has led to development of various novel therapies. Objective: The current treatments for RA fall into four categories: non-steroidal anti-inflammatory drugs, glucocorticoids, non-biological, disease-modifying anti-rheumatic drugs (DMARDs) and biological DMARDs. In this review, we discuss some of the most recent development in antirheumatic therapies. Methods: Using SciFinder Scholar and PubMed as our main search tools, we evaluated various newly developed therapies for RA. In each drug category, emphases are placed on the mode of action, limitations and new drug candidates from the patent search. Those therapies that are well-established are reviewed only briefly. Conclusion: During the past 20 years, most of the development of new therapies is in DMARDs, especially biological DMARDs. With the discovery of new pathways and the application of drug delivery strategies, more growth is anticipated in this research field.

AB - Background: Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease that affects approximately 0.5 - 1% of adults worldwide and commonly results in joint destruction and significant impairment in the quality of life. RA is considered an autoimmune disease with unknown etiology. Many pathogenic pathways of RA have been revealed recently, which has led to development of various novel therapies. Objective: The current treatments for RA fall into four categories: non-steroidal anti-inflammatory drugs, glucocorticoids, non-biological, disease-modifying anti-rheumatic drugs (DMARDs) and biological DMARDs. In this review, we discuss some of the most recent development in antirheumatic therapies. Methods: Using SciFinder Scholar and PubMed as our main search tools, we evaluated various newly developed therapies for RA. In each drug category, emphases are placed on the mode of action, limitations and new drug candidates from the patent search. Those therapies that are well-established are reviewed only briefly. Conclusion: During the past 20 years, most of the development of new therapies is in DMARDs, especially biological DMARDs. With the discovery of new pathways and the application of drug delivery strategies, more growth is anticipated in this research field.

KW - DMARDs

KW - Drug delivery

KW - Glucocorticoids

KW - NSAIDs

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=48049086545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48049086545&partnerID=8YFLogxK

U2 - 10.1517/13543776.18.7.723

DO - 10.1517/13543776.18.7.723

M3 - Review article

C2 - 19578469

AN - SCOPUS:48049086545

VL - 18

SP - 723

EP - 738

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 7

ER -